Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Lilly's Ramucirumab Gets Priority Review | Contract Pharma

What are you searching for?

Sign in
Trials & Filings

Lilly’s Ramucirumab Gets Priority Review

Represents potential advance in gastric cancer treatment

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Eli Lilly and Co.’s BLA for ramucirumab (IMC-1121B) as a single-agent treatment for advanced gastric cancer following disease progression after initial chemotherapy, has been assigned Priority Review by the FDA. Lilly anticipates agency action on this application in 2Q14. The priority designation aims to expedite the review of applications for drugs that, if approved, would represent a significant advance in treatment.

This BLA for ramucirumab was based on data from REGARD, a global, randomized, double-blind Phase III study of ramucirumab plus best supportive care compared to placebo plus best supportive care as a treatment in patients with advanced gastric cancer. A registration dossier is also under review by the EMA.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters